Description
SWOT ANALYSIS OF LUPIN
Lupin
Parent Company
Lupin
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Being lupin, enriching lives everyday
USP
Lupin is the world’s largest manufacturer of anti- tuberculosis drugs
STP
Anti TB segment, Cardiovascular, Oral and injectable, pediatric Segment products API’s, Anti-Infectives segment
Healthcare professionals, doctors treating patients suffering from TB, Target Group respiratory & cardiovascular diseases
It is innovation led pharmaceutical company, which specializes in Positioning generic, API & branded formulations for developed & developing world.
SWOT Analysis
1. World wide leader in Cephalosporin and Anti TB drugs 2. Considerable presence in market for drugs against Asthma, Pediatrics, Diabetes, and CNS boosts the sales 3. In the US and Japanese market it is the largest generic player 4. Acquisition of I’rom pharma helped to increase its product list and in turn sales Strength 5. Wide global footprint as it is present in over 70 countries
1.High dependence on global formulation business with 84% revenue coming from US market 3. Forecasting done on technological level is less Weakness 4. It operates in low growth segments such CNS, respiratory diseases
1.Increased health awareness 2. Emerging technological trends in drug delivery Opportunity 3. Increasing prevalence of TB in developing countries
Threats
1.Unsuccessful assimilation of questions
2.Rigid opposition both from locals and global company 3. Soaring cost of discovering novel products
Competition
1. Sun pharmaceuticals 2. Ranbaxy pharmaceuticals 3. Dr. Reddy’s lab Competitors 4. Cipla
doc_800729315.docx
SWOT ANALYSIS OF LUPIN
Lupin
Parent Company
Lupin
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Being lupin, enriching lives everyday
USP
Lupin is the world’s largest manufacturer of anti- tuberculosis drugs
STP
Anti TB segment, Cardiovascular, Oral and injectable, pediatric Segment products API’s, Anti-Infectives segment
Healthcare professionals, doctors treating patients suffering from TB, Target Group respiratory & cardiovascular diseases
It is innovation led pharmaceutical company, which specializes in Positioning generic, API & branded formulations for developed & developing world.
SWOT Analysis
1. World wide leader in Cephalosporin and Anti TB drugs 2. Considerable presence in market for drugs against Asthma, Pediatrics, Diabetes, and CNS boosts the sales 3. In the US and Japanese market it is the largest generic player 4. Acquisition of I’rom pharma helped to increase its product list and in turn sales Strength 5. Wide global footprint as it is present in over 70 countries
1.High dependence on global formulation business with 84% revenue coming from US market 3. Forecasting done on technological level is less Weakness 4. It operates in low growth segments such CNS, respiratory diseases
1.Increased health awareness 2. Emerging technological trends in drug delivery Opportunity 3. Increasing prevalence of TB in developing countries
Threats
1.Unsuccessful assimilation of questions
2.Rigid opposition both from locals and global company 3. Soaring cost of discovering novel products
Competition
1. Sun pharmaceuticals 2. Ranbaxy pharmaceuticals 3. Dr. Reddy’s lab Competitors 4. Cipla
doc_800729315.docx